section name header

Evidence summaries

Phosphodiesterase III Inhibitors for Heart Failure

Phosphodiesterase III inhibitor class drugs taken orally and long term are associated with increased deaths in heart failure. Level of evidence: "A"

A Cochrane review [Abstract] 1 included 21 studies with a total of 8408 subjects. Four specific phosphodiesterase III inhibitors (PDI) derivatives and 8 molecules of PDIs have been considered.

As compared with placebo, treatment with PDIs was found to be associated with a significant 17% increased mortality rate (The relative risk was 1.17 (95% confidence interval 1.06 to 1.30; p<0.001). In addition, PDIs significantly increase cardiac death, sudden death, arrhythmias and vertigos. Considering mortality from all causes, the deleterious effect of PDIs appears homogeneous whatever the concomitant use (or non-use) of vasodilating agents, the severity of heart failure, the derivative or the molecule of PDI used.

References

  • Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev. 2004;(4):CD002230.

Primary/Secondary Keywords